THE TWO-YEAR COVID-19 PANDEMIC: PROBLEMATIC ISSUES IN PEDIATRICS AND WAYS TO SOLVE THEM
DOI:
https://doi.org/10.11603/1681-2727.2022.2.13190Keywords:
вакцинаціяAbstract
SUMMARY. Based on a systematic review is a comprehensive search, data on the evolution of coronavirus infection of the XX century, taking into account etiological factors, clinical manifestations and diagnostic possibilities. The latest information on changes in the etiology of new coronavirus infection (COVID-19) during 2 years of the pandemic, the spread of the disease worldwide, international epidemiological principles, clinical symptoms, possible complications of the disease in pediatric practice.
The laboratory diagnostics of SARS-CoV-2 has been developed and improved by the efforts of the world medical community. The diagnostic criteria of different variants of the disease in children are described, taking into account general clinical, immunological, biochemical and instrumental methods of diagnosis. The phases of searching for etiological, pathogenetic, immunomodulatory therapy and its implementation in practice are highlighted. The treatment of complications, the use of oxygen therapy in acute respiratory distress syndrome, including ECMO in critical hypoxemia as a rescue technology. Emphasis is placed on the damage to various organs and systems in the acute phase of the disease, given the cytokine storm and the long-term effects of SARS-CoV-2, such as multisystem inflammatory syndrome. The stages of development of vaccines with different vectors of action against SARS-CoV-2 and their introduction into pediatric practice are given.
Today, there is a lot of information and research on COVID-19 in adults as opposed to children. That is why the review is devoted to SARS-CoV-2 infection in pediatric practice.
References
Nassar, M.S., Bakhrebah, M.A., Meo, S.A., Alsuabeyl, M.S., & Zaher, W.A. (2018). Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection: epidemiology, pathogenesis and clinical characteristics. European Review for Medical and Pharmacological Sciences, 22 (15), 4956-4961. https://doi.org/10.26355/eurrev_201808_15635
Ramanathan, K., Antognini, D., Combes, A., Paden, M., Zakhary, B., Ogino, M., Maclaren, G., & Brodie, D. (2020). Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet, 2020 (January), 19-21.
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T.S., Herrler, G., Wu, N.H., Nitsche, A., Müller, M.A., Drosten, C., & Pöhlmann, S. (2020). SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 181 (2), 271-280. e8. https://doi.org/10.1016/j.cell.2020.02.052
Biryukov, J., Boydston, J. A., Dunning, R.A., Yeager, J.J., Wood, S., Ferris, A., Miller, D., Weaver, W., Zeitouni, N.E., Freeburger, D., Dabisch, P., Wahl, V., Hevey, M.C., & Altamura, L.A. (2021). SARS-CoV-2 is rapidly inactivated at high temperature. Environmental Chemistry Letters, 19 (2), 1773-1777. https://doi.org/10.1007/s10311-021-01187-x
Cantuti-Castelvetri, L., Ojha, R., Pedro, L.D., Djannatian, M., Franz, J., Kuivanen, S., van der Meer, F., Kallio, K., Kaya, T., Anastasina, M., Smura, T., Levanov, L., Szirovicza, L., Tobi, A., Kallio-Kokko, H., Österlund, P., Joensuu, M., Meunier, F.A., Butcher, S.J., … Simons, M. (2020). Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science, 370 (6518), 856-860. https://doi.org/10.1126/science.abd2985
Conti, P., Ronconi, G., Caraffa, A., Gallenga, C., Ross, R., Frydas, I., & Kritas, S. (2020). Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. Journal of Biological Regulators and Homeostatic Agents, 34 (2), 327-331. https://doi.org/10.23812/CONTI-E
Parisi, G.F., Indolfi, C., Decimo, F., Leonardi, S., & Miraglia del Giudice, M. (2020). COVID-19 Pneumonia in Children: From Etiology to Management. Frontiers in Pediatrics, 8. https://doi.org/10.3389/fped.2020.616622
Garvin, M.R., Alvarez, C., Miller, J.I., Prates, E.T., Walker, A.M., Amos, B.K., Mast, A.E., Justice, A., Aronow, B., & Jacobson, D. (2020). A mechanistic model and therapeutic interventions for covid-19 involving a ras-mediated bradykinin storm. ELife, 9, 1-16. https://doi.org/10.7554/eLife.59177
Копча, В. С. (2021). Особливості Імунозалежних Проявів При Covid-19. Інфекційні Хвороби, 2(2), 4–16. https://doi.org/10.11603/1681-2727.2021.2.12159
Quinti, I., Mortari, E.P., Fernandez Salinas, A., Milito, C., & Carsetti, R. (2021). IgA Antibodies and IgA Deficiency in SARS-CoV-2 Infection. Frontiers in Cellular and Infection Microbiology, 11(April), 1-5. https://doi.org/10.3389/fcimb.2021.655896
Berksoy, E., Kanik, A., Çiçek, A., Bardak, Ş., Elibol, P., Demir, G., Yilmaz, N., Nalbant, T., Gökalp, G., & Yilmaz Çiftdoğan, D. (2021). Clinical and laboratory characteristics of children with SARS-CoV-2 infection. Pediatric Pulmonology, 56 (12), 3674-3681. https://doi.org/10.1002/ppul.25654
Jone, P.-N., John, A., Oster, M.E., Allen, K., Tremoulet, A.H., Saarel, E.V., Lambert, L.M., Miyamoto, S.D., & de Ferranti, S.D. (2022). SARS-CoV-2 Infection and Associated Cardiovascular Manifestations and Complications in Children and Young Adults: A Scientific Statement From the American Heart Association. Circulation, 145 (19). https://doi.org/10.1161/CIR.0000000000001064
Rodriguez-Gonzalez, M., Castellano-Martinez, A., Cascales-Poyatos, H.M., & Perez-Reviriego, A.A. (2020). Cardiovascular impact of COVID-19 with a focus on children: A systematic review. In World Journal of Clinical Cases (Vol. 8, Issue 21). https://doi.org/10.12998/wjcc.v8.i21.5250
Zaffanello, M., Piacentini, G., Nosetti, L., Ganzarolli, S., & Franchini, M. (2021). Thrombotic risk in children with COVID-19 infection: A systematic review of the literature. Thrombosis Research, 205 (January), 92-98. https://doi.org/10.1016/j.thromres.2021.07.011
Aguilera-Alonso, D., Murias, S., Martínez-De-Azagra Garde, A., Soriano-Arandes, A., Pareja, M., Otheo, E., Moraleda, C., Tagarro, A., & Calvo, C. (2021). Prevalence of thrombotic complications in children with SARS-CoV-2. Archives of Disease in Childhood, 106 (11), 1129-1132. https://doi.org/10.1136/archdischild-2020-321351
Feldstein, L.R., Rose, E.B., Horwitz, S.M., Collins, J.P., Newhams, M.M., Son, M.B.F., Newburger, J.W., Kleinman, L.C., et al. (2020). Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. New England Journal of Medicine, 383 (4), 334-346. https://doi.org/10.1056/nejmoa2021680
Bertoncelli, D., Guidarini, M., Della Greca, A., Ratti, C., Falcinella, F., Iovane, B., Luigi Dutto, M., Caffarelli, C., & Tchana, B. (2020). Covid19: Potential cardiovascular issues in pediatric patients. Acta Biomedica, 91 (2), 177-183. https://doi.org/10.23750/abm.v91i2.9655
Pereira, M.F.B., Litvinov, N., Farhat, S.C.L., Eisencraft, A.P., Gibelli, M.A. B.C., de Carvalho, W.B., Fernandes, V.R., et al. (2020). Severe clinical spectrum with high mortality in pediatric patients with covid-19 and multisystem inflammatory syndrome. Clinics, 75, 1-7. https://doi.org/10.6061/clinics/2020/e2209
Toubiana, J., Poirault, C., Corsia, A., Bajolle, F., Fourgeaud, J., Angoulvant, F., Debray, A., et al. (2020). Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study. BMJ (Clinical Research Ed.), 369, m2094. https://doi.org/10.1136/bmj.m2094
Xie, J., Ding, C., Li, J., Wang, Y., Guo, H., Lu, Z., Wang, J., Zheng, C., Jin, T., Gao, Y., & He, H. (2020). Characteristics of patients with coronavirus disease (COVID-19) confirmed using an IgM-IgG antibody test. Journal of Medical Virology, 92 (10), 2004-2010. https://doi.org/10.1002/jmv.25930
Soldati, G., & Demi, M. (2022). What Is COVID 19 Teaching Us about Pulmonary Ultrasound? Diagnostics, 12 (4), 838. https://doi.org/10.3390/diagnostics12040838
Malin, J.J., Suárez, I., Priesner, V., Fätkenheuer, G., & Rybniker, J. (2020). Remdesivir against COVID-19 and Other Viral Diseases. Clinical Microbiology Reviews, 34 (1). https://doi.org/10.1128/CMR.00162-20
Paladugu, S., & Donato, A.A. (2020). Remdesivir improved time to recovery in adults hospitalized with COVID-19 and lower respiratory tract involvement. Annals of Internal Medicine, 173 (2), JC4. https://doi.org/10.7326/ACPJ202007210-005
Nori, P., Cowman, K., Chen, V., Bartash, R., Szymczak, W., Madaline, T., Punjabi Katiyar, C., Jain, R., et al. (2021). Bacterial and fungal coinfections in COVID-19 patients hospitalized during the New York City pandemic surge. Infection Control and Hospital Epidemiology, 42 (1), 84-88. https://doi.org/10.1017/ice.2020.368
The RECOVERY Collaborative Group. (2020). Dexamethasone in Hospitalized Patients with Covid-19 – Preliminary Report. New England Journal of Medicine, 693-704.
https://doi.org/10.1056/nejmoa2021436ELSO, E. (n.d.). European Survey on ECMO in COVID-19 pts at 7/05/20. Available in: Https://Www.Euroelso.Net/Covid-19/Covid-19-Survey/.Accessed at 10 de Mayo de 2020.
ECLS. Registry Dashboard of ECMO-Supported COVID-19 Patient Data. Https://Www.Elso.Org/Registry/FullCOVID-19RegistryDashboard.Aspx.
Dalton, H.J., Reeder, R., Garcia-Filion, P., Holubkov, R., Berg, R.A., Zuppa, A., Moler, F.W., et al. (2017). Factors associated with bleeding and thrombosis in children receiving extracorporeal membrane oxygenation. American Journal of Respiratory and Critical Care Medicine, 196 (6), 762-771. https://doi.org/10.1164/rccm.201609-1945OC
Hottz, E.D., Azevedo-Quintanilha, I.G., Palhinha, L., Teixeira, L., Barreto, E.A., Pão, C.R.R., et al. (2020). Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19. Blood, 136 (11), 1330-1341. https://doi.org/10.1182/blood.2020007252
Karimi, M., Bozorgi, H., Zarei, T., Bordbar, M., Amanati, A., Safaei, A., & De Sanctis, V. (2020). Antithrombotic prophylaxis in children and adolescent patients with sars-cov-2 (Covid-19) infection: A practical guidance for clinicians. Acta Biomedica, 91 (4), 1-8. https://doi.org/10.23750/abm.v91i4.10720
De Rose, D.U., Piersigilli, F., Ronchetti, M.P., Santisi, A., Bersani, I., Dotta, A., Danhaive, O., & Auriti, C. (2020). Novel Coronavirus disease (COVID-19) in newborns and infants: what we know so far. Italian Journal of Pediatrics, 46 (1), 56. https://doi.org/10.1186/s13052-020-0820-x
Kabeerdoss, J., Pilania, R.K., Karkhele, R., Kumar, T.S., Danda, D., & Singh, S. (2021). Severe COVID-19, multisystem inflammatory syndrome in children, and Kawasaki disease: immunological mechanisms, clinical manifestations and management. Rheumatology International, 41 (1), 19-32. https://doi.org/10.1007/s00296-020-04749-4
МІНІСТЕРСТВО ОХОРОНИ ЗДОРОВ’Я УКРАЇНИ. (n.d.). Наказ МОЗ України від 20.09.2021 № 1979 “Про внесення змін до протоколу «Надання медичної допомоги для лікування коронавірусної хвороби (COVID-19)».” Https://Moz.Gov.Ua/Article/Ministry-Mandates/Nakaz-Moz-Ukraini-Vid-20092021--1979-pro-Vnesennja-Zmin-Do-Protokolu--Nadannja-Medichnoi-Dopomogi-Dlja-Likuvannja--Koronavirusnoi-Hvorobi-Covid-19?Preview=1.
Banerji, A., Wickner, P.G., Saff, R., Stone, C.A., Robinson, L.B., Long, A.A., Wolfson, A.R., et al. (2021). mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach. The Journal of Allergy and Clinical Immunology: In Practice, 9 (4), 1423-1437. https://doi.org/10.1016/j.jaip.2020.12.047
Міністерство Охорони Здоровя України. (n.d.). В Україні рекомендували щепити від COVID-19 дітей 12+ за наявності усіх рутинних щеплень. Https://Moz.Gov.Ua/Article/News/29 Жовтня 2021.
https://www.fda.gov/news-events/press-announcements/. (n.d.). FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Children 5 through 11 Years of Age. October 29, 2021.
Ramasamy, M.N., Minassian, A.M., Ewer, K.J., Flaxman, A.L., Folegatti, P.M., Owens, D.R., Voysey, M., et al. (2020). Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. The Lancet, 396 (10267), 1979-1993. https://doi.org/10.1016/S0140-6736(20)32466-1
Han, B., Song, Y., Li, C., Yang, W., Ma, Q., Jiang, Z., Li, M., et al. (2021). Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial. The Lancet Infectious Diseases, 21 (12), 1645-1653. https://doi.org/10.1016/S1473-3099(21)00319-4
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Infectious diseases
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Journal Infectious Disease (Infektsiini Khvoroby) allows the author(s) to hold the copyright without registration
Users can use, reuse and build upon the material published in the journal but only for non-commercial purposes
This journal is available through Creative Commons (CC) License BY-NC "Attribution-NonCommercial" 4.0
